Global Cutaneous Mastocytosis Treatment Market, By Product Type (Cell Therapy, Gene Therapy, Tissue Engineering and Small Molecule & Biologic), type (Antihistamines, Corticosteroids, Mast Cell Stabilizers, Sympathomimetic Agents (Ephinephrine) and Photo Chemotherapy), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Cutaneous Mastocytosis Treatment Market Analysis and Size
Cutaneous mastocytosis is a relatively unknown condition typically involving infants under two years of age, making it hard to detect. Treatment and diagnosis of mastocytosis of the skin is disturbed by a lack of understanding between health workers and the general public. Over the last decade, numerous governments and NGOs have raised much awareness of mast cell diseases, and the diagnosis rate has risen intensely since then.
Data Bridge Market Research analyses a growth rate in the cutaneous mastocytosis treatment market in the forecast period 2023-2030. The expected CAGR of cutaneous mastocytosis treatment market is tend to be around 3.6% in the mentioned forecast period. The market was valued at USD 272.7 million in 2022, and it would grow upto USD 361.88 million by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cutaneous Mastocytosis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Cell Therapy, Gene Therapy, Tissue Engineering and Small Molecule & Biologic), type (Antihistamines, Corticosteroids, Mast Cell Stabilizers, Sympathomimetic Agents (Ephinephrine) and Photo Chemotherapy), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Viatris Inc (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc (U.S.), Sanofi (France), Bayer AG (Germany), Mallinckrodt (U.K.), Apotex Inc (Canada), EPI Health (U.S.) and kaleo, Inc (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Cutaneous mastocytosis is a rare disease for which there is no long-lasting cure. Still, numerous medications such as proton pump inhibitors, antihistamines, steroids, and others are being used to relieve symptoms. Top market companies are increasing their investments in R&D to discover therapeutic substitutes that can successfully eliminate the symptoms of cutaneous mastocytosis.
Global Cutaneous Mastocytosis Treatment Market Dynamics
Drivers
- Increased Adoption of Photochemotherapy
Even though there is no permanent cure for cutaneous mastocytosis, photochemotherapy has been recognized as an effective combination of the drug psoralens and long-wave ultraviolet radiation for this condition. Photochemotherapy has shown promising outcomes and is progressively being used as a latest treatment option for the disease. This trend is expected to fuel market growth during the forecast period.
- Increasing Awareness About Cutaneous Mastocytosis
The increasing awareness about the disease , its diagnosis, and treatment is expanding the market growth. The better understanding of the symptoms and treatment has encouraged parents of infants to ask for medical attention, which is boosting the rate of diagnosis and treatment requirements in these cases. Numerous non-profit organizations and government entities are highlighting spreading awareness about cutaneous mastocytosis, which is expected to promote market growth in the coming years.
Opportunities
- Growing R&D Activities
Growing investment in research and drug development by several major market players to discover innovative treatment options for cutaneous mastocytosis is likely to expand the market growth during the forecast period. Numerous novel diagnostic and prognostic factors are being established to make therapy easier and more efficient. Additionally, new advancements in pathogenesis are likely to create new opportunities for improved disease management, promoting the market expansion.
- Several Treatment Alternatives For Cutaneous Mastocytosis
Several treatments such as antihistamines, proton pump inhibitors, Epinephrine, tyrosine kinase inhibitors, and steroids have become the main options for treating and relieving multiple symptoms of systemic mastocytosis. They are being gradually consumed by patients suffering from systemic mastocytosis to improve their quality of life.
Restraints/Challenges
- High Cost of Treatment Processes
The cost of treatment and the medications necessary to relieve the symptoms of the disease is extremely expensive. Photochemotherapy is developing as a popular treatment option for cutaneous mastocytosis; but a patient with this condition requires 10 to 15 sessions every month, that is not affordable for the underdeveloped countries. Consequently, the high cost of therapy and medication is a primary impediment to market expansion.
- Side Effects of Photochemotherapy
There are some severe side effects that are associated with photochemotherapy which somehow decrease the market growth. Effects such as burning, itching, nausea, tanning, pregnancy, psoriasis hamper the treatment adoption.
This cutaneous mastocytosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cutaneous mastocytosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Cutaneous Mastocytosis Treatment Market
The COVID-19 has impacted the healthcare sector harshly. While clinical trials for rare diseases are postponed through 2020 as priority was given to the development of lifesaving drugs, the market for cutaneous mastocytosis is expected to witness a short-term fall even during 2021.
The COVID-19 pandemic had a negative impact on the market. The reductions in the frequency of consultations for treatment at hospitals affected the market but in the post pandemic era, the number of patients seeking treatments has increased.
Global Cutaneous Mastocytosis Treatment Market Scope
The cutaneous mastocytosis treatment market is segmented on the basis of product type, type, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Cell Therapy
- Gene Therapy
- Tissue Engineering
- Small Molecule & Biologic
Type
- Antihistamines
- Corticosteroids
- Mast Cell Stabilizers
- Sympathomimetic Agents (Ephinephrine)
- Photo Chemotherapy
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Cutaneous Mastocytosis Treatment Market Regional Analysis/Insights
The cutaneous mastocytosis treatment market is analyzed and market size insights and trends are provided by product type, type, end-user, distribution channel as referenced above.
The major countries covered in the cutaneous mastocytosis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to rise in the healthcare outcomes, rise in the R&D activities, rise in number of patients with systemic mastocytosis and increasing awareness about diseases and new product launches in this region.
Asia-Pacific dominates the market due to increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and presence of generic manufacturers.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cutaneous Mastocytosis Treatment Market Share Analysis
The cutaneous mastocytosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cutaneous mastocytosis treatment market.
Key players operating in the cutaneous mastocytosis treatment market include:
- Novartis AG (Switzerland)
- Viatris Inc (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- Bausch Health Companies Inc. (Canada )
- Pfizer Inc (U.S.)
- Sanofi (France)
- Bayer AG (Germany)
- Mallinckrodt plc (U.K.)
- Apotex Inc (Canada)
- EPI Health (U.S.)
- kaleo, Inc (U.S.)
SKU-